Fit for Purpose: HIV treatment optimisation for adults and children (2017)
14 August 2017. Related: Supplements.
2017
i-Base 2017 appeal: we need your help….
10 August 2017. Related: Special reports.
9th IAS Conference on HIV Science (IAS 2017)
10 August 2017. Related: Conference reports.
HIV pipeline drugs: IAS 2017 update
10 August 2017. Related: Conference reports, Antiretrovirals.
Darunavir/cobicistat/FTC/TAF: 24-week interim results from phase 3 switch study
10 August 2017. Related: Conference reports, Antiretrovirals.
Phase 3 results with bictegravir FDC: a new integrase inhibitor combined with FTC/TAF
10 August 2017. Related: Conference reports, Antiretrovirals.
Doravirine/3TC/TDF compared to efavirenz/FTC/TDF as first-line ART
10 August 2017. Related: Conference reports, Antiretrovirals.
Continued viral suppression with long-acting cabotegravir/rilpivirine injections: 96-week LATTE-2 results
10 August 2017. Related: Conference reports, Antiretrovirals.
Reduced-dose darunavir is safe and effective in switch study
10 August 2017. Related: Conference reports, Antiretrovirals.
MK-8591: further compelling early results for both treatment and prevention
10 August 2017. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.
Dolutegravir outperforms lopinavir/ritonavir second-line: interim results from the DAWNING study
10 August 2017. Related: Conference reports, Antiretrovirals, Treatment strategies, Treatment access.
Preliminary results on dolutegravir use in pregnancy are reassuring
10 August 2017. Related: Conference reports, Pregnancy.
Low dose efavirenz (EFV400) can be used during pregnancy
10 August 2017. Related: Conference reports, Pregnancy.
Stillbirth rate in HIV positive women in UK/Ireland is double that of the general population
10 August 2017. Related: Conference reports, Pregnancy.
Swaziland nearly halves HIV incidence in five years
10 August 2017. Related: Conference reports, Treatment access.
Gay men with undetectable viral load do not transmit HIV: Opposites Attract study supports U=U
10 August 2017. Related: Conference reports, HIV prevention and transmission.
HIV remission news from IAS 2017
10 August 2017. Related: Conference reports, Cure-related research, Basic science and immunology.
Publications launched at IAS 2017
10 August 2017. Related: Conference reports, Drug resistance, Other news.
9th International Workshop on HIV Paediatrics, 21–22 July 2017, Paris
10 August 2017. Related: Conference reports, Paediatric care.
Chewable raltegravir tablets can be crushed and dispersed in liquid for young children
10 August 2017. Related: Conference reports, Paediatric care.
Inconsistencies between real-world data from UK and Ireland and EU recommendations for new antiretrovirals in pregnancy
10 August 2017. Related: Conference reports, Pregnancy.
First dolutegravir-based generic FDC gets FDA tentative approval
10 August 2017. Related: Antiretrovirals, Treatment access.
FDA grant priority review for ibalizumab
10 August 2017. Related: Antiretrovirals.
Controversial PrEP study from NHS England due to start in September
10 August 2017. Related: HIV prevention and transmission.
UK hepatitis A outbreak in gay men: shortages of HAV and HBV vaccines escalated to ‘national incident’
10 August 2017. Related: Hepatitis coinfection.
July/August 2017: Volume 18 Number 7/8
10 August 2017. Related: PDFs.
FDA approves sofosbuvir/velpatasvir/voxilaprevir (Vosevi) second-line DAA HCV treatment in the US in the US
1 August 2017. Related: Hepatitis coinfection.
HIV pipeline report 2017
20 July 2017. Related: Special reports, Supplements, Pipeline report, Antiretrovirals.
HIV pipeline 2017: full version
20 July 2017. Related: Special reports, Supplements, Pipeline report, Antiretrovirals.
HIV pipeline 2017: summary version
20 July 2017. Related: Supplements, Pipeline report, Antiretrovirals.
HIV pipeline 2017: Update from IAS Paris
20 July 2017. Related: Supplements, Pipeline report, Antiretrovirals.
HIV pipeline 2017 PDFs
20 July 2017. Related: Supplements, Pipeline report, PDFs.
Fit for purpose (July 2017)
20 July 2017. Related: Special reports, Supplements, Pipeline report, Fit for purpose.
Antiretroviral treatment optimisation for adults and children
20 July 2017. Related: Supplements, Fit for purpose.
HIV pipeline 2017: summary version
20 July 2017. Related: Supplements, Fit for purpose.
The paediatric pipeline 2017
20 July 2017. Related: Supplements, Fit for purpose.
Fit for purpose 2017 PDF
20 July 2017. Related: Supplements, Fit for purpose, PDFs.
May/June 2017: Volume 18 Number 5/6
26 June 2017. Related: Editorial.
ART in pictures: HIV treatment explained (June 2017)
26 June 2017. Related: Supplements.
Unexpected side effects with generic abacavir – and potential for rare reactions to other generic ARVs
26 June 2017. Related: Treatment alerts, Antiretrovirals, Side effects.
18th International Workshop on Clinical Pharmacology of Antiviral Therapy, 14-16 June 2017, Chicago
26 June 2017. Related: Conference reports.
Dolutegravir pharmacokinetics in pregnancy
26 June 2017. Related: Conference reports, Antiretrovirals, Pregnancy, PK and drug interactions.
High rates of of undocumented efavirenz-related side effects in Uganda
26 June 2017. Related: Conference reports, Antiretrovirals, Side effects.
11th INTEREST Workshop, 16-19 May 2017, Lilongwe, Malawi
26 June 2017. Related: Conference reports.
Increased risk of ART failure after low-level viraemia in a large South African cohort
26 June 2017. Related: Conference reports, Antiretrovirals.
Option B+ Malawi
26 June 2017. Related: Conference reports, Antiretrovirals, Pregnancy.
24th Conference on Retroviruses and Opportunistic Infections (CROI 2017), 13-16 February 2017, Seattle
26 June 2017. Related: Conference reports.
Impressive HIV pipeline at CROI 2017
26 June 2017. Related: Conference reports, Coinfections and complications.
Paediatric HIV: CROI 2017
26 June 2017. Related: Conference reports, Coinfections and complications.
WHO adds dolutegravir and PrEP to updated Essential Medicine List
26 June 2017. Related: Treatment access.
Dolutegravir/rilpivirine submitted to EMA and FDA as oral two-drug maintenance combination
26 June 2017. Related: Antiretrovirals.
Bictegravir/FTC/TAF: new once-daily integrase-based FDC submitted to US FDA
26 June 2017. Related: Antiretrovirals.
FDA updates cobicistat and Stribild labels: interactions with systemic, inhaled, nasal and ophthalmic corticosteriods
26 June 2017. Related: Antiretrovirals, PK and drug interactions.
Increased prevalence of diabetes in HIV positive people
26 June 2017. Related: Coinfections and complications.
Poppers and cancer risk in HIV negative and HIV positive gay men
26 June 2017. Related: Coinfections and complications, Cancer and HIV.
Case report of capsulitis with elvitegravir and cobicistat (EVG/c)
26 June 2017. Related: Side effects.
Natural history of elite controllers
26 June 2017. Related: Basic science and immunology.
Evidence of smaller HIV reservoirs in a Ugandan cohort
26 June 2017. Related: Cure-related research.
HIV superinfection is associated with specific HLA types
26 June 2017. Related: HIV prevention and transmission, Basic science and immunology.
New study of combined HIV prevention and contraception ring
26 June 2017. Related: HIV prevention and transmission.
FDA approves sofosbuvir/ledipasvir and sofosbuvir for children aged 12 to 17
26 June 2017. Related: Paediatric care, Hepatitis coinfection.
Cochrane review of HCV treatment misses real issues of access to care
26 June 2017. Related: Treatment access, Hepatitis coinfection.
King’s Fund report on HIV services in England
26 June 2017. Related: Other news.
Toolkit to support doctors against immigration interventions in the NHS
26 June 2017. Related: Other news.
Hepatology – a clinical textbook (8th edition, 2017)
26 June 2017. Related: On the web.